{"id":194537,"name":"TIBER CREEK GROUP (ON BEHALF OF VERTEX PHARMACEUTICALS)","slug":"tiber-creek-group-on-behalf-of-vertex-pharmaceuticals","state":"DC","description":"Government relations.","totalSpending":1560000,"filings":29,"yearlySpending":[{"year":2018,"income":60000},{"year":2019,"income":80000},{"year":2020,"income":80000},{"year":2021,"income":180000},{"year":2022,"income":320000},{"year":2023,"income":320000},{"year":2024,"income":240000},{"year":2025,"income":280000}],"firms":["TIBER CREEK HEALTH STRATEGIES, INC."],"lobbyists":["JAMES HALL"],"issues":["MMM","HCR",null],"sampleDescriptions":["Issues related to rare diseases (cystic fibrosis); Issues related to pharmaceutical pricing","Issues related to rare diseases (cystic fibrosis.","Issues related to rare diseases (cystic fibrosis)","Issues related to rare diseases (Cystic fibrosis).","Issues related to pharmaceutical pricing.","Issues related to the Prescription Drug Pricing Reduction Act","Issues related to Part D redesign","Issues related to the Prescription Drug Pricing Reduction Act, HR 1865 - Consolidated Appropriations Act (PL 116-94)","Issues related to the Prescription Drug Pricing Reduction Act; HR 6201 Families First Coronavirus Response Act (PL 116-27) - drug pricing issues; CARES Act - S. 3548 (PL 116-136) - drug pricing issues.","CARES Act - S. 3548 (PL 116-136) - drug pricing issues. H.R. 6800 the Health and Economic Recovery Omnibus Emergency Solutions Act","Issues relating to drug pricing","Issues relating to drug pricing; H.R. 133 / PL 116-260 - FY2021 Omnibus and COVID Relief and Response Act","Issues relating to drug pricing; H.R. 133/PL 116-260 - FY2021 Omnibus and COVID Relief and Response Act.","Issues related to Part D redesign.","Issues related to Medicaid drug pricing.","Issues related to implementation of drug pricing and reimbursement for prescription drugs in Inflation Reduction Act of 2022 (PL 117-169)."],"years":[2018,2019,2020,2021,2022,2023,2024,2025]}